Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $12.9 million.

  • Enanta Pharmaceuticals' Capital Expenditures fell 83.71% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 28.15%. This contributed to the annual value of $12.9 million for FY2025, which is 28.15% down from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Capital Expenditures is $12.9 million, which was down 28.15% from $17.9 million recorded in FY2024.
  • Enanta Pharmaceuticals' Capital Expenditures' 5-year high stood at $17.9 million during FY2024, with a 5-year trough of $750,000 in FY2021.
  • Its 3-year average for Capital Expenditures is $13.3 million, with a median of $12.9 million in 2025.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Capital Expenditures tumbled by 48.10% in 2021 and then skyrocketed by 326.26% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Capital Expenditures (Yearly) stood at $750,000 in 2021, then skyrocketed by 183.33% to $2.1 million in 2022, then surged by 326.26% to $9.1 million in 2023, then spiked by 98.15% to $17.9 million in 2024, then decreased by 28.15% to $12.9 million in 2025.